Alimentary pharmacology & therapeutics
-
Aliment. Pharmacol. Ther. · Sep 2012
Anti-tumour necrosis factor treatment of inflammatory bowel disease in liver transplant recipients.
Ulcerative colitis (UC) and Crohn's disease can sometimes relapse and be refractory to standard treatment following orthotopic liver transplantation (OLT) despite post-transplantation immunosuppressive therapy. ⋯ Starting Anti-TNF therapy following orthotopic liver transplantation appears to be a potential option for inflammatory bowel disease management. Additional studies are needed, however, to confirm these findings and to further assess risks associated with this treatment strategy.
-
Aliment. Pharmacol. Ther. · Sep 2012
Case ReportsMesenteric phlebosclerosis associated with long-term oral intake of geniposide, an ingredient of herbal medicine.
Idiopathic mesenteric phlebosclerosis (IMP) is a rare disease, characterised by thickening of the wall of the right hemicolon with calcification of mesenteric veins. However, the aetiology remains unknown. ⋯ The long-term use of geniposide in herbal medicines appears to be associated with mesenteric phlebosclerosis.
-
Aliment. Pharmacol. Ther. · Aug 2012
Randomized Controlled TrialRandomised clinical trial: simvastatin as adjuvant therapy improves significantly the Helicobacter pylori eradication rate--a placebo-controlled study.
The eradication rate of Helicobacter pylori with standard treatments are decreasing worldwide. ⋯ In this randomised clinical trial simvastatin as adjuvant to standard therapy improves significantly the H. pylori eradication rate.
-
Aliment. Pharmacol. Ther. · Jul 2012
Case ReportsThe safety and efficacy of antitumour necrosis factor-alpha therapy for inflammatory bowel disease in patients post liver transplantation: a case series.
The role of antitumour necrosis factor-alpha (anti-TNF) therapy for inflammatory bowel disease (IBD) among liver transplant recipients is largely unknown given the rarity of this population and the paucity of literature on the subject. ⋯ Based on this case series, anti-TNF therapy appears to be safe and effective for treating refractory IBD in patients post liver transplantation. These patients respond to anti-TNF therapy similar to those who have not been previously transplanted.